ABOUT US
Transforming Precision Medicine with Multimodal AI
BioAI is a biotechnology company employing world-leading AI technology to map the causal biology of disease, develop digital biomarkers and identify novel drug targets for the development of better medicine.
Our Mission
At BioAI, our mission is to develop AI-powered precision biomarkers and discover novel drug targets to accelerate clinical R&D and to revolutionize precision medicine.
Our Purpose
Our purpose is to develop novel AI solutions for precision medicine to improve patient care and quality of life.
Our Values
Innovation
We are dedicated to excellence in innovation, driving the continuous advancement of AI technologies in precision medicine, and staying at the forefront of scientific and technological breakthroughs in Biopharma.
Patient Empowerment
We are on a journey to improve patient outcomes. At BioAI, we are committed to empowering patients with more personalized treatment options, conquering cancer one data point at a time.
Integrity
Upholding the highest ethical standards is essential in our field where research and development directly impact patient care and also often involve sensitive information. From partner and patient confidentiality to ethical AI, we maintain integrity in all aspects of operations.
Collaboration
BioAI believes in the power of interdisciplinary collaboration and teamwork bringing together experts from multiple fields and fostering relationships with healthcare providers, research institutions and biopharmaceutical partners.
PEOPLE
Meet the Team
Meet our leadership team, scientific advisory board, and growing board of industry experts and partners. Our multidisciplinary team has expertise across machine learning, medicine, and biology.
Leadership Team
Board of Advisors
Hon. Prof. Tom Chittenden, PhD, DPhil, DSPE
SAB Chairman, CSO at BullFrog AI, Honorary Professor of AI in Biomedicine, Queen Mary University of London
Paolo Ascierto, MD
Director of the Department of Melanoma Cancer Immunotherapy, Institute of National Tumor IRCCS Foundation
Carlo Bifulco, MD
Chief Medical Officer of Providence Genomics, Medical Director, Translational Pathology, Earle A. Chiles Research Institute
Greg Slabaugh, PhD
Professor, and Director of the Digital Environment Research Institute (DERI), Queen Mary University of London
